secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001558370-24-001752
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M
-----------------------------------------------------------------------------

- Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.
- Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).
- Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.
- Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.
- Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/0001558370-24-001752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/acrs-20240227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer